We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Plexus (PLXS) to Report Q2 Earnings: Key Factors to Note
Read MoreHide Full Article
Plexus Corp (PLXS - Free Report) is slated to report fiscal second-quarter 2024 results on Apr 24.
The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $951.3 million, which suggests a decline of 11.2% from the year-ago quarter’s reported figure. The consensus mark for earnings per share (EPS) is pegged at 77 cents, indicating a year-over-year decrease of 46.9%.
The company’s earnings beat the Zacks Consensus Estimate in all the last four quarters. It has a trailing four-quarter earnings surprise of 13.3%, on average.
For fiscal second-quarter 2024, the company projects revenues between $$930 million and $970 million. GAAP diluted EPS is expected to be in the range of 48-63 cents.
Plexus’s performance in the fiscal second quarter is likely to have benefited from new manufacturing contract wins. In the last reported quarter, the company won 30 manufacturing contracts worth $261 million in annualized revenues when fully ramped into production. Also, trailing four-quarter manufacturing wins totaled more than $1.05 million in annualized revenues.
The company anticipates its Aerospace and Defense segment to gain momentum owing to new program ramps and rising demand for its solutions in commercial aerospace amid weakness in the semiconductor capital equipment market. Also, the funnel of qualified manufacturing is expected to have benefited from customers outsourcing their internal manufacturing.
However, the company’s performance is likely to have been affected due to uncertainty prevailing over global macroeconomic conditions, geopolitical instability and supply-chain disruptions. Customer concentration risks and stiff competition are further concerns.
The company expects mid-single digits decline in second for its Healthcare/Life Sciences sector due to near-term demand weakness and inventory corrections. The company expects the Industrial sector to decline sequentially by low-single digits in the fiscal second quarter.
What Our Model Says
Our proven model does not predict an earnings beat for PLXS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here.
PLXS has an Earnings ESP of 0.00% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are some stocks that you may consider, as our proven model shows that these also have the right mix of elements to beat on estimates this time around.
The Zacks Consensus Estimate for IMAX’s to-be-reported quarter’s earnings and revenues is pegged at 8 cents per share and $75.8 million, respectively. Shares of IMAX have gained 41.2% in the past year.
Meta Platforms (META - Free Report) has an Earnings ESP of +0.62% and presently carries a Zacks Rank #2. META is slated to release quarterly numbers on Apr 24.
The Zacks Consensus Estimate for META’s to-be-reported quarter’s earnings and revenues is pegged at $4.32 per share and $36.22 billion, respectively. Shares of META have lost 5.1% in the past year.
Lam Research Corporation (LRCX - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #2. LRCX is set to report quarterly figures on Apr 24.
The Zacks Consensus Estimate for LRCX’s to-be-reported quarter’s earnings and revenues is pegged at $7.23 per share and $3.70 billion, respectively. Shares of LRCX have surged 107.2% in the past year.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Plexus (PLXS) to Report Q2 Earnings: Key Factors to Note
Plexus Corp (PLXS - Free Report) is slated to report fiscal second-quarter 2024 results on Apr 24.
The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $951.3 million, which suggests a decline of 11.2% from the year-ago quarter’s reported figure. The consensus mark for earnings per share (EPS) is pegged at 77 cents, indicating a year-over-year decrease of 46.9%.
The company’s earnings beat the Zacks Consensus Estimate in all the last four quarters. It has a trailing four-quarter earnings surprise of 13.3%, on average.
For fiscal second-quarter 2024, the company projects revenues between $$930 million and $970 million. GAAP diluted EPS is expected to be in the range of 48-63 cents.
Plexus Corp. Price and EPS Surprise
Plexus Corp. price-eps-surprise | Plexus Corp. Quote
Factors to Note
Plexus’s performance in the fiscal second quarter is likely to have benefited from new manufacturing contract wins. In the last reported quarter, the company won 30 manufacturing contracts worth $261 million in annualized revenues when fully ramped into production. Also, trailing four-quarter manufacturing wins totaled more than $1.05 million in annualized revenues.
The company anticipates its Aerospace and Defense segment to gain momentum owing to new program ramps and rising demand for its solutions in commercial aerospace amid weakness in the semiconductor capital equipment market. Also, the funnel of qualified manufacturing is expected to have benefited from customers outsourcing their internal manufacturing.
However, the company’s performance is likely to have been affected due to uncertainty prevailing over global macroeconomic conditions, geopolitical instability and supply-chain disruptions. Customer concentration risks and stiff competition are further concerns.
The company expects mid-single digits decline in second for its Healthcare/Life Sciences sector due to near-term demand weakness and inventory corrections. The company expects the Industrial sector to decline sequentially by low-single digits in the fiscal second quarter.
What Our Model Says
Our proven model does not predict an earnings beat for PLXS this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, this is not the case here.
PLXS has an Earnings ESP of 0.00% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are some stocks that you may consider, as our proven model shows that these also have the right mix of elements to beat on estimates this time around.
IMAX Corporation (IMAX - Free Report) has an Earnings ESP of +56.00% and currently carries a Zacks Rank #2. IMAX is scheduled to report quarterly earnings on Apr 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for IMAX’s to-be-reported quarter’s earnings and revenues is pegged at 8 cents per share and $75.8 million, respectively. Shares of IMAX have gained 41.2% in the past year.
Meta Platforms (META - Free Report) has an Earnings ESP of +0.62% and presently carries a Zacks Rank #2. META is slated to release quarterly numbers on Apr 24.
The Zacks Consensus Estimate for META’s to-be-reported quarter’s earnings and revenues is pegged at $4.32 per share and $36.22 billion, respectively. Shares of META have lost 5.1% in the past year.
Lam Research Corporation (LRCX - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #2. LRCX is set to report quarterly figures on Apr 24.
The Zacks Consensus Estimate for LRCX’s to-be-reported quarter’s earnings and revenues is pegged at $7.23 per share and $3.70 billion, respectively. Shares of LRCX have surged 107.2% in the past year.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.